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We have reported that autophagy is crucial for clearance of amyloidogenic human IAPP
(hIAPP) oligomer, suggesting that an autophagy enhancer could be a therapeutic modality
against human diabetes with amyloid accumulation. Here, we show that a recently identified
autophagy enhancer (MSL-7) reduces hIAPP oligomer accumulation in human induced
pluripotent stem cell-derived β-cells (hiPSC-β-cells) and diminishes oligomer-mediated
apoptosis of β-cells. Protective effects of MSL-7 against hIAPP oligomer accumulation and
hIAPP oligomer-mediated β-cell death are significantly reduced in cells with knockout of
MiTF/TFE family members such as Tfeb or Tfe3. MSL-7 improves glucose tolerance and β-cell
function of hIAPP+ mice on high-fat diet, accompanied by reduced hIAPP oligomer/amyloid
accumulation and β-cell apoptosis. Protective effects of MSL-7 against hIAPP oligomer-
mediated β-cell death and the development of diabetes are also significantly reduced by β-
cell-specific knockout of Tfeb. These results suggest that an autophagy enhancer could have
therapeutic potential against human diabetes characterized by islet amyloid accumulation.
https://doi.org/10.1038/s41467-020-20454-z OPEN
1 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. 2 Department of Internal Medicine, Yonsei University College of
Medicine, Seoul, Korea. 3 Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan
University School of Medicine, Seoul, Korea. 4 Department of Endocrinology and Metabolism, College of Medicine, The Catholic University of Korea,
Seoul, Korea. 5 Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea. 6 Transplantation Center, Sungkyunkwan University School
of Medicine, Seoul, Korea. 7 Department of Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea. 8 Department of Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 9Department of Chemistry, Gwangju Institute of Science and Technology,
Gwangju, Korea. ✉email: mslee0923@yuhs.ac









While most studies on the basic pathogenic mechanismof diabetes employ mouse models in which geneticmodulation is possible, human diabetes and mouse
diabetes are different in several key features. For instance, the
structure and function of pancreatic islets are different between
mouse models and humans1. Such differences may be responsible
for the failure of antidiabetic drugs developed using mouse
models in human clinical trials. One of the most intriguing dif-
ferences between mouse models of diabetes and human diabetes
is the deposition of amyloid in islets of human patients with
diabetes but not in those of mouse models. Islet amyloid
deposition is observed in over 90% of human diabetes patients
but not in murine diabetes, which is due to the differences in the
amino acid sequences of the islet amyloid polypeptide (IAPP)2.
Others and we previously reported that human-type IAPP
(hIAPP) oligomer or amyloid accumulation in transgenic mice
expressing hIAPP (hIAPP+ mice) or hIAPP knock-in mice in
which endogenous murine IAPP gene was replaced by hIAPP
markedly increases when β-cell autophagy is deficient, suggesting
that autophagy is critical in the clearance of hIAPP oligomer or
amyloid3–5. These data are consistent with a proposition that
aggregate or amyloid-prone proteins are preferentially cleared by
autophagy rather than proteasomal degradation6. These results
also suggest the possibility that autophagy enhancers may be
employed as a therapeutic modality against human diabetes
characterized by islet amyloid accumulation. Indeed, we have
observed that trehalose that has been reported to have autophagy-
enhancing activity7 could ameliorate metabolic profile of hIAPP+
mice fed high-fat diet (HFD). However, trehalose has been
developed as a chaperoning agent or hydrating agent, and its
autophagy enhancing activity has been questioned in a recent
paper8.
We recently identified and developed bona fide autophagy
enhancer small molecules in a high-throughput screening of a
chemical library that can have beneficial metabolic effects in
obese mouse models by enhancing clearance of lipid and ameli-
orating metabolic inflammation. These effects were attributed to
calcineurin-dependent dephosphorylation and activation of TFEB
that belongs to the MiTF/TFE family and is a master regulator of
lysosome biogenesis and autophagy gene expression9. Here, we
studied whether our autophagy enhancer small molecule, MSL-7,
could expedite clearance of hIAPP oligomer in pancreatic islets
and protect β-cells in transgenic mice showing hIAPP accumu-
lation. We found that MSL-7 improved the glucose tolerance and
β-cell function of hIAPP+ mice rendered diabetic by HFD feed-
ing, which was accompanied by reduced accumulation of hIAPP
oligomer and islet amyloid. These results suggest that an autop-
hagy enhancer acting in a TFEB-dependent manner could have a
therapeutic potential against human diabetes characterized by
islet amyloid accumulation.
Results
Dephosphorylation and nuclear translocation of TFEB and
TFE3 by autophagy enhancer, MSL-7. We first studied whether
MSL-7 can induce autophagy in INS-1 insulinoma cells. Confocal
microscopy after transfection of INS-1 cells with mRFP-GFP-LC3
tandem construct showed that the numbers of both autophago-
somes (yellow puncta) and autophagolysosomes (red puncta)
were significantly increased after treatment with MSL-7 (Fig. 1a),
indicating that MSL-7 induces autophagic activity in INS-1 cells.
Conversion of LC3-I to LC3-II in the presence of bafilomycin
A1was also increased by MSL-7 (Fig. 1b and Supplementary
Fig. 1a), supporting increased autophagic flux by MSL-7. Since
TFEB, a member of MiTF/TFE family, is a master regulator of
autophagy gene expression and lysosomal biogenesis10 and TFEB
is expressed in primary murine islet cells (Supplementary Fig. 2a,
b), we studied TFEB activation in INS-1 cells. As expected, a
significant increase of the number of INS-1 cells with nuclear
TFEB was observed after treatment with MSL-7 (Fig. 1c), indi-
cating that MSL-7 activates autophagy of INS-1 cells through
TFEB nuclear translocation. Probably because of TFEB activation,
expression of SQSTM1 (also known as p62), a target of TFEB11,
was not reduced but increased by MSL-7 despite activation of
autophagy (Fig. 1b and Supplementary Fig. 1a). We next studied
TFE3, another member of the MiTF/TFE family regulating
autophagy gene expression and lysosomal biogenesis12, which is
also expressed in primary murine islets (Supplementary Fig. 2a,
b). Translocation of TFE3 was also well observed after MSL-7
treatment of INS-1 cells (Fig. 1d). Since the phosphorylation
status of MiTF/TFE family members is critical in nuclear trans-
location and induction of their target genes, we studied phos-
phorylation of MiTF/TFE family members. When we studied
phosphorylation of S142 of TFEB, one of the most important
phosphorylation sites of TFEB13, S142 phosphorylation was
markedly reduced by MSL-7 (Fig. 1e and Supplementary Fig. 1b),
which was consistent with previous data using other types of
cells9. We also studied phosphorylation of S211 of TFEB, another
important phosphorylation site of TFEB, using immunoprecipi-
tation assay based on the binding of the phospho-S211 motif of
TFEB to 14-3-3 protein14. Band intensity of 14-3-3 protein
identified by immunoblotting with anti-14-3-3 antibody in TFEB
immunoprecipitate, thus TFEB-bound 14-3-3 protein, was
markedly reduced by MSL-7 (Fig. 1f and Supplementary Fig. 1c),
indicating decreased phosphorylation of S211 of TFEB by MSL-7.
Band intensity of TFEB with 14-3-3 binding motif identified by
immunoblotting with anti-phospho-(Ser) 14-3-3 binding motif
antibody in TFEB immunoprecipitate, thus phospho-S211-
TFEB14 was also markedly reduced by MSL-7 (Fig. 1f and Sup-
plementary Fig. 1c), again supporting decreased phosphorylation
of S211 of TFEB by MSL-7. We next studied the phosphorylation
of TFE3 using a similar immunoprecipitation assay based on the
binding of phospho-S321 motif of TFE3 to 14-3-3 protein12.
Band intensity of 14-3-3 protein identified by immunoblotting
with anti-14-3-3 antibody in TFE3 immunoprecipitate, thus
TFE3-bound 14-3-3 protein, and that of TFE3 with 14-3-3
binding motif identified by immunoblotting with anti-phospho-
(Ser) 14-3-3 binding motif antibody in TFE3 immunoprecipitate,
thus phospho-S321-TFE312, were notably reduced by MSL-7
(Fig. 1f and Supplementary Fig. 1c). Markedly increased nuclear
translocation of TFEB and TFE3 likely due to reduced phos-
phorylation upon treatment of INS-1 cells with MSL-7 was
confirmed by immunoblot analysis after nuclear fractionation
(Fig. 1g and Supplementary Fig. 1d). Reduced phosphorylation of
S211-TFEB or S321-TFE3 by MSL-7 was also observed when
Tfeb-GFP or Tfe3-GFP was overexpressed in INS-1 cells using the
same immunoprecipitation assay employing anti-GFP antibody
(Fig. 1h and Supplementary Fig. 1e). Consequently, nuclear
translocation of TFEB-GFP or TFE3-GFP was markedly
increased after MSL-7 treatment (Fig. 1i), similar to the nuclear
translocation of endogenous TFEB or TFE3. Treatment with
MSL-7 inducing nuclear translocation of TFEB and TFE3 upre-
gulated expression of several autophagy genes and lysosomal
genes downstream of MiTF/TFE family members such as Uvrag,
Becn 1, Sqstm1, Map1lc3, Lamp1, Mcoln1, Ctsa, or Atp6v1h
(Fig. 1j and Supplementary Table 1). Expression of Tfeb or Tfe3
themselves was also induced by MSL-7 (Fig. 1j).
Expedited clearance of hIAPP oligomer by MSL-7. We pre-
viously reported that pro-human IAPP (hIAPP) dimer or trimer
accumulates when prepro-hIAPP encoding amyloidogenic hIAPP
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is expressed in INS-1 insulinoma cells3 which could be the initial
seed for hIAPP oligomer, fibril or amyloid15,16. Thus, we studied
whether MSL-7 could reduce the pro-hIAPP dimer or trimer
accumulation. When INS-1 cells were transfected with prepro-
hIAPP-HA, pro-hIAPP dimer was observed in addition to hIAPP
monomer (Fig. 2a and Supplementary Fig. 1f), consistent with a
previous report3. When INS-1 cells were transfected with prepro-
murine IAPP (mIAPP)-HA, only mIAPP monomer was observed,
as expected. When INS-1 cells were incubated with MSL-7,
accumulation of the pro-hIAPP dimer following transfection with
prepro-hIAPP-HA was notably decreased compared to control
cells (Fig. 2a and Supplementary Fig. 1f). Decreased accumulation
of pro-hIAPP dimer by MSL-7 was reversed by bafilomycin A1
inhibiting lysosomal V-ATPase (Fig. 2a and Supplementary
Fig. 1f), suggesting that enhanced autophagic activity or lysoso-
mal proteolysis is responsible for reduced pro-hIAPP dimer
accumulation. In addition to pro-hIAPP dimer, pro-hIAPP tri-
mer was also observed in the presence of bafilomycin A1(Fig. 2a
and Supplementary Fig. 1f), consistent with an important role of
constitutive autophagy in the clearance of pro-hIAPP dimer and
trimer3. We also studied whether MSL-7 can ameliorate cell death
by hIAPP oligomer accumulation which can be augmented by 3-
MA increasing hIAPP oligomer accumulation3. When INS-1 cells
were incubated with MSL-7, cell death determined by oligonu-
cleosome release following transfection with prepro-hIAPP in the
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Fig. 1 Activation of TFEB/TFE3 by MSL-7. a INS-1 cells were transfected with mRFP-GFP-LC3. The numbers of yellow (autophagosomes) and red puncta
(autophagolysosomes) were counted (t= 9.8, df= 38 for autophagosome; t= 17.2, df= 38 for autophagolysosome) (right). Representative pictures are
presented (left). Inset images were magnified. b INS-1 cells were treated with MSL-7 in the presence or absence of bafilomycin A1 (BAF). Immunoblotting
using the indicated antibodies (ACTB, β-actin) were conducted. Numbers indicate fold changes normalized to ACTB bands. c–d Nuclear translocation of
TFEB (c) and TFE3 (d) by MSL-7 was counted (t= 29.9, df= 12 in c; t= 38.7, df= 12 in d) (right of c, d). Representative pictures are shown (left of c, d).
e INS-1 cells were treated with MSL-7, and immunoblotting using the indicated antibodies were conducted. Numbers indicate fold changes normalized to
total TFEB bands. f After lysis of INS-1 cells treated with MSL-7 for 4 h, immunoprecipitation (IP) was conducted using anti-TFEB (left) or anti-TFE3
antibody (right). Supernatant was subjected to immunoblot analysis (IB) using the indicated antibodies. Numbers indicate fold changes normalized to total
TFEB or TFE3 bands. g Nuclear and cytosolic fractions of lysates from INS-1 cells treated with MSL-7 were subjected to immunoblot analysis using the
indicated antibodies. Numbers indicate fold changes normalized to ACTB bands (cytosol) or Lamin bands (nuclear). h After lysis of Tfeb-GFP-transfected
(left) or Tfe3-GFP-transfected cells (right) treated with MSL-7, IP using anti-GFP antibody was conducted. i After treatment of Tfeb-GFP-transfected or
Tfe3-GFP-transfected cells with MSL-7, confocal microscopy was conducted. Numbers indicate fold changes normalized to GFP bands. j Real-time RT-PCR
was performed using mRNA from INS-1 cells treated with MSL-7 for 6 h and specific primers. All data in this figure are the means ± SEM from more than 3
independent experiments performed in triplicate. (scale bar, 5 μm) *P < 0.05; **P < 0.01; ***P < 0.001 by two-tailed Student’s t-test (a, c, d, j). Source data
are provided as a Source Data file.
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Fig. 2 hIAPP/sIAPP oligomer clearance by MSL-7. a Prepro-mIAPP-HA-transfected or Prepro-hIAPP-HA-transfected INS-1 cells were treated with MSL-7 in
the presence or absence of bafilomycin A1 (BAF). Lysate was subjected to immunoblotting using anti-HA or anti-β-actin antibody (ACTB). Numbers
indicate fold changes of hIAPP dimer normalized to ACTB bands. (Con, control-transfected). b Prepro-mIAPP-HA-transfected or Prepro-hIAPP-HA-
transfected cells were treated with MSL-7 in the presence or absence of 3-MA. Oligonucleosome content was determined (F= 19.5, df treatment= 11, df
residual= 36). c–dMSL-7-induced nuclear translocation of TFEB (c) and TFE3 (d) in monkey islet cells was counted (t= 33.2, df= 14 in c; t= 45.7, df= 14
in d) (right of c, d). Representative pictures are presented (left of c, d). e mRFP-GFP-LC3-transfected monkey islet cells were treated with MSL-7. The
numbers of autophagosome (t= 9.5, df= 44) and autophagolysosome (t= 10.9, df= 44) were counted (right). Representative pictures are presented
(left). Inset images were magnified to show red (autophagolysosomes) and yellow (autophagosomes) puncta. f Monkey islet cells treated with MSL-7 in
the presence or absence of 3-MA were subjected to immunostaining using A11 antibody. The number of A11+ puncta was counted (F= 86.3, df
treatment= 2, df residual= 42) (right). Representative pictures are presented (left). g Monkey islet cells treated with MSL-7 in the presence of BAF, cells
were immunostained using A11 and anti-LC3 antibodies. The number of LC3 puncta colocalized with A11+ oligomer was counted (t= 13.9, df= 38) (right).
Representative pictures are shown (left). Inset images were magnified to shows LC3 puncta colocalized with A11+ oligomer. h Apoptosis was determined in
MSL-7-treated monkey islet cells in the presence or absence of 3-MA (F= 10.1, df treatment= 3, df residual= 20). All data in this figure are the means ±
SEM from more than 3 independent experiments performed in triplicate. (scale bar, 5 μm) *P < 0.05; **P < 0.01; ***P < 0.001 by one-way ANOVA with
Tukey’s test (b, f, h) and two-tailed Student’s t-test (c, d, e, g). Source data are provided as a Source Data file.
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could be due to decreased accumulation of toxic hIAPP oligo-
mer17 by MSL-7. Without 3-MA, cell death was not observed
after transfection with prepro-hIAPP which is probably due to the
effective clearance of hIAPP oligomer by constitutive autophagy
(Fig. 2b), consistent with a previous report3.
To study effect of MSL-7 on IAPP oligomer clearance in a
more physiological setting, we next studied whether MSL-7 can
expedite clearance of endogenous IAPP oligomer. To this end, we
employed monkey islet cells expressing amyloidogenic simian
IAPP (sIAPP) that is almost identical to hIAPP3,18. When we
studied whether MSL-7 induces the nuclear translocation of
MiTF/TFE family members in monkey islet cells using confocal
microscopy, markedly increased nuclear TFEB and TFE3 was
observed after treatment with MSL-7 (Fig. 2c, d), similar to the
results employing INS-1 cells. When we examined whether MSL-
7 can induce autophagic activity in monkey islet cells using
confocal microscopy upon transfection with mRFP-GFP-LC3
tandem construct, the numbers of both autophagosomes and
autophagolysosomes were significantly increased after treatment
with MSL-7 (Fig. 2e), indicating that MSL-7 increases autophagic
activity of monkey islet cells, similar to the results employing
INS-1 cells. When primary monkey islet cells were cultured in the
presence of 3-MA, sIAPP oligomer stained with A11 antibody
recognizing hIAPP oligomer19 significantly accumulated which
was not seen without 3-MA (Fig. 2f), suggesting that amyloido-
genic sIAPP oligomer in monkey islet cells is constitutively
cleared by autophagy. When monkey islet cells cultured in the
presence of 3-MA were treated with MSL-7, accumulation of
sIAPP oligomer was significantly reduced (Fig. 2f), suggesting
that MSL-7 could expedite clearance of endogenous sIAPP
oligomer. Furthermore, confocal microscopy after immunofluor-
escence revealed markedly increased colocalization of LC3 with
A11+ sIAPP oligomer after treatment with MSL-7 in the presence
of bafilomycin A1 inhibiting lysosomal degradation of sIAPP
oligomer (Fig. 2g), supporting that sIAPP oligomer is cleared by
autophagy. Apoptosis of monkey islet cells incubated with 3-MA
probably due to accumulation of endogenous sIAPP oligomer3
was also significantly attenuated by MSL-7 (Fig. 2h), supporting
that sIAPP oligomer is cleared by MSL-7-induced autophagy and
that MSL-7-mediated reduction of sIAPP oligomer accumulation
leads to the amelioration of cell death.
While behavior of sIAPP oligomer would be similar to that of
hIAPP oligomer, we further investigated effect of MSL-7 on
hIAPP oligomer clearance employing human β-cells or β-cell
lines. We chose 1.1B4 cells that have been generated by
electrofusion of human primary pancreatic islet cells to human
pancreatic adenocarcinoma cells and express hIAPP20, instead of
EndoC-βH1 cells that were derived from human fetal pancreas by
SV40LT and human TERT transduction but virtually express no
hIAPP21. MSL-7 treatment induced nuclear translocation of
TFEB or TFE3, and enhanced formation of autophagosomes or
autophagolysosomes in 1.1B4 cells (Supplementary Fig. 3a–c).
MSL-7 reduced hIAPP oligomer accumulation and apoptosis in
1.1B4 cells incubated with 3-MA enhancing hIAPP oligomer
accumulation (Supplementary Fig. 3d, e). MSL-7 induced
expression of autophagy genes, lysosomal genes and TFEB or
TFE3 in 1.1B4 cells (Supplementary Fig. 3f and Supplementary
Table 2), showing that MSL-7 effectively induced target genes of
TFEB or TFE3, and enhanced clearance of hIAPP oligomer in
human β-cells as well.
Since behavior of 1.1B4 cells fused to pancreatic cancer cells
could be different from normal human islet cells, we next used
human islet cells differentiated from donor-derived human
induced pluripotent stem cells (hiPSCs)22. hiPSCs were differ-
entiated into β-cells using a kit (STEMdiffTM Pancreatic
Progenitor Kit, STEMCELL Technologies) according to a
modification of previously reported methods23,24, which was
confirmed by immunofluorescence using anti-insulin antibody
(hiPSC-β-cells) (Fig. 3a and Supplementary Fig. 4a, b). The
percentage of human insulin-producing cells among islet-like
clusters was 7–8% (Supplementary Fig. 4b). When islet-like
clusters differentiated from hiPSCs were incubated with 3-MA,
hIAPP oligomer accumulation was clearly seen in insulin-
producing cells as yellow puncta in double immunofluorescence
using A11 and anti-insulin antibodies (Fig. 3b). Combined
treatment with MSL-7 significantly reduced A11+ hIAPP
oligomer accumulation in hiPSC-β-cells producing insulin
(Fig. 3b). Reduced hIAPP oligomer accumulation was accom-
panied by nuclear translocation of TFEB and TFE3 as identified
by immunofluorescence using specific antibodies, which can be
seen as reduced cytosolic yellow fluorescence due to colocaliza-
tion of insulin with TFEB or TFE3 and increased cyan
fluorescence due to colocalization of nuclear DAPI with TFEB
or TFE3 after MSL-7 treatment (Fig. 3a). When we determined
apoptosis of hiPSC-β-cells in the presence of 3-MA cyan
increasing A11+ hIAPP oligomer accumulation, percentage of
TUNEL+ apoptotic cells (identified as cyan nuclei) among
insulin+ cells was significantly reduced by MSL-7 (Fig. 3c),
supporting that MSL-7 reduces human β-cell apoptosis by
enhancing hIAPP oligomer clearance.
Diminution of MSL-7 effects by Tfeb-knockout or Tfe3-
knockout. Since MSL-7 induces the nuclear translocation of
TFEB and TFE3, critical regulators of lysosome biogenesis and
autophagy gene expression, in pancreatic islet cells or INS-1
insulinoma cells, we next studied the role of MiTF/TFE family
members in the accelerated clearance of hIAPP oligomer and
improved viability of islet cells. To this end, we produced INS-1
cells with Tfeb-knockout or Tfe3-knockout (KO) using
CRISPR/Cas9 technology. Immunoblot analysis demonstrated
the absence of TFEB or TFE3 expression in Tfeb-KO or Tfe3-
KO cells, respectively (Supplementary Fig. 5a). Nucleotide
sequencing showed a deletion of 116 bp segment between the
two sgRNA target loci of Tfeb and an insertion of 120 bp donor
sequences to an sgRNA target locus of Tfe3 (Supplementary
Fig. 5b), which led to the decrease and increase of the band sizes
of PCR product using flanking primer sequences, respectively
(Supplementary Fig. 5c). Expression and nuclear translocation
of TFE3 were not affected in Tfeb-KO cells, while those of TFEB
were not affected in Tfe3-KO cells (Fig. 4a). When Tfeb-KO or
Tfe3-KO INS-1 cells were transfected with mRFP-GFP-LC3
plasmid and treated with MSL-7, the numbers of autophago-
some and autophagolysosome were decreased in both Tfeb-KO
and Tfe3-KO cells compared to control cells (Fig. 4b), sug-
gesting reduced autophagic flux by Tfeb-KO or Tfe3 KO. Fur-
thermore, induction of autophagy genes and lysosomal genes by
MSL-7 treatment was reduced in Tfeb-KO or Tfe3-KO INS-1
cells compared to control Cas9-treated cells, accounting for the
decrease of MSL-7-induced autophagy in these cells (Supple-
mentary Fig. 6a–i).
We also studied whether Tfeb or Tfe3 KO affects hIAPP
oligomer clearance by MSL-7. When cells were transfected with
prepro-hIAPP-HA, intensity of hIAPP dimer bands before MSL-7
treatment was notably higher in both Tfeb-KO and Tfe3-KO INS-
1 cells compared to control cells (compare 3rd with 7th or 11th
lane from the left of Fig. 4c, left panel; Supplementary Fig. 1g,
upper panel), probably because of reduced constitutive clearance
of hIAPP dimer. When Tfeb-KO or Tfe3-KO INS-1 cells
transfected with prepro-hIAPP-HA were treated with MSL-7,
decreases of hIAPP dimer band intensity relative to vehicle
(Veh)-treated Tfeb-KO or Tfe3-KO cells were small and
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statistically insignificant in both KO cells (compare 7th with 8th
lane or 11th with 12th lane from the left of Fig. 4c, left panel;
Supplementary Fig. 1g, upper panel). Thus, when normalized to
the vehicle-treated respective KO cells, intensity of hIAPP dimer
band after treatment of Tfeb-KO or Tfe3-KO INS-1 cells with
MSL-7 was significantly higher than that after treatment of wild-
type control cells with MSL-7 (compare 2nd with 4th or 6th bar
from the left of Fig. 4c, right panel; Supplementary Fig. 1g, lower
panel), suggesting diminished MSL-7 effect on hIAPP dimer
clearance by Tfeb or Tfe3 KO. Likely due to reduced constitutive
clearance of hIAPP dimer, a small but significant apoptosis was
observed after transfection of Tfeb-KO or Tfe3-KO INS-1 cells
with prepro-hIAPP in the absence of 3-MA (compare 9th and
11th bars from the left of Fig. 4d, left and right panels), which was
not observed in Tfeb-KO or Tfe3-KO cells transfected with
prepro-mIAPP (compare 5th and 7th bars from the left of Fig. 4d,
left and right panels) or autophagy-competent wild-type cells
transfected with prepro-hIAPP (compare 1st and 9th bars from
the left in the left and right panels of Fig. 4d). Apoptosis of Tfeb-
KO or Tfe3-KO INS-1 cells after prepro-hIAPP transfection (in
the absence of 3-MA) was not significantly reduced by MSL-7
(compare 11th and 12th bars from the left of Fig. 4d, left and right
panels), likely due to decreases of MSL-7-induced autophagy in
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Fig. 3 Effect of MSL-7 on the clearance of endogenous hIAPP oligomer in human β-cells differentiated from hiPSCs. a Expression of insulin and nuclear
translocation of TFEB (left) or TFE3 (right) in human β-cells differentiated from human induced pluripotent stem cells (hiPSCs). Inset images were
magnified to show cyan nuclei due to colocalization of TFEB with nuclear DAPI or yellow cytoplasm due to colocalization of TFEB with insulin+ cytoplasm.
b Islet-like clusters differentiated from hiPSCs were treated with MSL-7 in the presence or absence of 3-MA for 16 h. After double immunofluorescence
using A11 and anti-insulin antibodies as the primary antibodies, confocal microscopy was conducted and the number of A11+ puncta in insulin-producing β-
cells was counted (F= 357.2, df treatment= 3, df residual= 76) (lower). Representative pictures are presented (upper). Inset images were magnified.
c After treatment of islet-like clusters differentiated from hiPSCs cells with MSL-7 in the presence or absence of 3-MA for 16 h, combined TUNEL staining
and insulin immunofluorescence were conducted, and the percentage of TUNEL+ apoptotic cells among insulin-producing β-cells was counted (F= 150.3,
df treatment= 3, df residual= 76) (lower). Representative pictures are presented (upper). Inset images were magnified to show cyan nuclei due to
colocalization of TUNEL staining with nuclear DAPI. All data in this figure are the means ± SEM from more than 3 independent experiments. (n= 20 islet-
like clusters in a, b, c) (scale bar, 50 μm for a and 100 μm for b, c) ***P < 0.001 by one-way ANOVA with Tukey’s test.
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prepro-hIAPP transfection in the presence of 3-MA was also not
significantly reduced by MSL-7 (compare 7th and 8th or 11th and
12th bars from the left of Fig. 4e), which is different from a
significant decrease of prepro-hIAPP-transfected control INS-1
cell apoptosis in the presence of 3-MA by MSL-7 (compare 3rd
and 4th bars from the left of Fig. 4e; see also Fig. 2b) and is
probably due to reduced MSL-7-mediated autophagy in Tfeb-KO
or Tfe3-KO INS-1 cells. Residual effect of MSL-7 in Tfeb-KO or
Tfe3-KO INS-1 cells such as induction of low-level autophagy
(Fig. 4b) and small increases of autophagy gene or lysosomal gene
expression (Supplementary Fig. 6a–i) could be due to other
members of MiTF/TFE family such as MiTF25 that is expressed in
pancreatic islet cells at a low level (Supplementary Fig. 2a, b).
Furthermore, TFE3 expression is intact in Tfeb-KO cells and
TFEB expression is intact in Tfe3-KO cells (Supplementary
Fig. 5a), which can explain residual induction of autophagy in
Tfeb-KO or Tfe3-KO cells. However, autophagy induction in
these cells was significantly reduced compared to wild-type cells,
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Effect of MSL-7 on transgenic mice expressing amyloidogenic
hIAPP. Based on the in vitro results showing accelerated clear-
ance of hIAPP oligomer by MSL-7, we next studied whether
MSL-7 can improve the metabolic profile of transgenic mice
expressing hIAPP in pancreatic β-cells (hIAPP+ mice) rendered
diabetic by HFD. In vivo administration of 50 mg/kg MSL-7 3
times a week for 8 weeks (Fig. 5a) significantly decreased non-
fasting and fasting glucose levels in hIAPP+ mice on HFD, while
Fig. 4 Reduced MSL-7 effects in Tfeb-KO or Tfe3-KO cells in vitro. a Tfeb-KO or Tfe3-KO INS-1 cells were treated with MSL-7 for 4 h, and immunostained
using anti-TFEB (left) or anti-TFE3 antibody (right). After DAPI staining, cells were subjected to confocal microscopy. b Tfeb-KO or Tfe3-KO INS-1 cells
transfected with mRFP-GFP-LC3 tandem construct were treated with MSL-7 for 16 h, and the numbers of autophagosome and autophagolysosome were
counted (F= 178.7, df treatment= 5, df residual= 114) (right). Representative pictures are presented (left). Inset images were magnified to show red
(autophagolysosomes), green, and yellow (autophagosomes) puncta. c Tfeb-KO or Tfe3-KO INS-1 cells transfected with prepro-mIAPP-HA or prepro-hIAPP-
HA were treated with MSL-7 for 16 h. Immunoblot analysis was conducted (F= 32.9, df treatment= 5, df residual= 12) (left). Densitometric value of HA
bands normalized to the respective vehicle-treated cells (−) are presented (right). d Tfeb-KO (left) or Tfe3-KO (right) INS-1 cells transfected with prepro-
mIAPP-HA or prepro-hIAPP-HA were treated with MSL-7 for 16 h without 3-MA, and apoptosis was measured (F= 5.8, df treatment= 11, df residual= 36 in
left panel; F= 11.3, df treatment= 11, df residual= 36 in right panel). e Tfeb-KO or Tfe3-KO INS-1 cells transfected with prepro-mIAPP-HA or prepro-hIAPP-
HA were treated with MSL-7 for 16 h in the presence of 3-MA, and apoptosis was measured (F= 24.1, df treatment= 11, df residual= 36). All data in this
figure are the means ± SEM from more than 3 independent experiments performed in triplicate. (scale bar, 5 μm) *P < 0.05; **P < 0.01; ***P < 0.001 by one-
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Fig. 5 Metabolic effect of MSL-7 on hIAPP+ mice. a Scheme of MSL-7 treatment. b MSL-7 was administered intraperitoneally (i.p.) to HFD-fed male hIAPP+
mice. Nonfasting blood glucose was monitored (F= 35.0, df= 3). c Fasting blood glucose was determined in HFD-fed hIAPP+ mice treated with MSL-7 for
8 weeks (F= 14.3, df treatment= 3, df residual= 28). d Body weight of HFD-fed hIAPP+ mice was monitored during MSL-7 administration. e GTT was
performed after MSL-7 administration to HFD-fed hIAPP+ mice (F= 24.4, df= 3) (left). AUC was calculated (F= 22.3, df treatment= 3, df residual= 28)
(right). f Insulinogenic index was calculated after MSL-7 administration to HFD-fed hIAPP+ mice (F= 29.2, df treatment= 3, df residual= 28) (left). Serum
insulin levels before and 15min after glucose injection are shown (right). g Islets were isolated from HFD-fed hIAPP+ and hIAPP− mice treated with vehicle (Veh)
or MSL-7, and were subjected to respirometry using Seahorse XF analyzer (left). Basal (F= 13.7, df treatment= 3, df residual= 18), glucose-stimulated (F= 19.1,
df treatment= 3, df residual= 18), ATP-coupled (F= 12.4, df treatment= 3, df residual= 18) and maximal O2 consumption (F= 23.7, df treatment= 3, df
residual= 18) were calculated. All data in this figure are the means ± SEM from more than 3 independent experiments. (n= 7 for Veh-treated hIAPP− mice, n=
7 for MSL-7-treated hIAPP− mice, n= 9 for Veh-treated hIAPP+ mice and n= 9 for MSL-7-treated hIAPP+ mice in b–f; n= 5 for Veh-treated hIAPP− mice, n= 5
for MSL-7-treated hIAPP− mice treated, n= 6 for Veh-treated hIAPP+ mice and n= 6 for MSL-7-treated hIAPP+ mice in g) *P < 0.05; ##P or **P < 0.01; ###P or
***P < 0.001 by two-way ANOVA with Bonferroni’s test (b, e) and one-way ANOVA with Tukey’s test (c, e, f, g). (#, comparison between Veh-treated hIAPP+
and Veh-treated hIAPP− mice; *, comparison between MSL-7-treated hIAPP+ and Veh-treated hIAPP+ mice in b, e).
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body weight was not significantly changed (Fig. 5b–d). Glucose
tolerance test (GTT) showed that glucose intolerance in HFD-fed
hIAPP+ mice was significantly ameliorated by MSL-7, accom-
panied by reduced area under the curve (AUC) (Fig. 5e). Insu-
linogenic index (the difference between serum insulin 0 and 15
min after glucose infusion divided by the difference between
blood glucose 0 and 15 min after glucose infusion) representing
β-cell function which was reduced in hIAPP+ mice on HFD
(Fig. 5f), was also significantly improved by MSL-7 (Fig. 5f),
suggesting that improved pancreatic β-cell function could explain
amelioration of glucose intolerance of hIAPP+ mice on HFD by
MSL-7 treatment. We also studied possible effect of MSL-7 on
mitochondrial dysfunction caused by hIAPP oligomer26,27 which
can affect glucose-induced insulin release28. Seahorse respiro-
metry showed that basal, glucose-stimulated, ATP-coupled or
maximal O2 consumption was suppressed in islets of hIAPP+
mice fed HFD (Fig. 5g), suggesting mitochondrial dysfunction of
β-cells in these mice. Here, MSL-7 treatment in vivo ameliorated
suppression of basal, glucose-stimulated, ATP-coupled or max-
imal O2 consumption of pancreatic islet cells of hIAPP+ mice on
HFD, which could be due to increased turnover of dysfunctional
mitochondria through autophagy activation and lead to improved
β-cell function in these mice (Fig. 5g).
We did not observe improvement of metabolic indexes by
MSL-7 administration to hIAPP− mice on HFD for 8 weeks
(Fig. 5a–f), which is different from significant metabolic
improvement in C57BL/6 mice on HFD for 16 weeks by MSL-7
administration9. This discrepancy could be due to strain
difference between C57BL/6 and FVB/N mice29 or duration of
HFD feeding (8 vs. 16 weeks). Indeed, glucose tolerance
determined by AUC of GTT curves was significantly impaired
by HFD feeding of C57BL/6 mice for 8 weeks but not by that of
FVB/N mice (Supplementary Fig. 7a). Furthermore, nonfasting
blood glucose in FVB/N mice fed HFD for 8 weeks was not
significantly elevated compared to that in the same mice fed
normal chow diet (NCD) for 8 weeks (Supplementary Fig. 7b),
suggesting that significant insulin resistance was not induced by
HFD feeding of mice of FVB/N background and that effect of
MSL-7 in hIAPP+ mice on HFD is due to its effect on β-cell
function associated with hIAPP clearance but not due to
improved insulin sensitivity. Consistently, we observed no effect
of MSL-7 administration on insulin sensitivity of hIAPP− or
hIAPP+ mice on HFD as evidenced by no change of AUC of
insulin tolerance test (ITT) curves by MSL-7 administration to
hIAPP− or hIAPP+ mice on HFD (Supplementary Fig. 7c), again
indicating that metabolic improvement by MSL-7 administration
to hIAPP+ mice is due to improved β-cell function but not due to
improved insulin sensitivity. AUC of ITT curves was reduced in
HFD-fed hIAPP+ mice compared to HFD-fed hIAPP− mice both
before (compare gray and blue curve or bar) and after (compare
green and red curve or bar) MSL-7 administration showing
reduced insulin sensitivity of HFD-fed hIAPP+ mice (Supple-
mentary Fig. 7c), probably because elevated blood glucose level in
HFD-fed hIAPP+ mice itself can reduce insulin sensitivity30.
To investigate whether improved glucose profile and β-cell
function in vivo by MSL-7 administration were due to the
increased clearance of toxic hIAPP oligomer, we conducted
immunofluorescence of pancreatic islets using A11 antibody.
A11+ hIAPP oligomer accumulation in pancreatic islets of
hIAPP+ mice on HFD was significantly reduced by in vivo
administration of MSL-7 for 8 weeks (Fig. 6a). Some islet cells
with A11+ hIAPP oligomer had pyknotic nuclei, suggesting
occurrence of apoptosis by hIAPP oligomer accumulation
(Fig. 6a). Amyloid staining using (E,E)-1-fluoro-2,5-bis(3-hydro-
xycarbonyl-4-hydroxy) styrylbenzene (FSB) showed that pan-
creatic islet amyloid accumulation observed in hIAPP+ mice on
HFD was also significantly reduced by in vivo administration of
MSL-7 for 8 weeks (Fig. 6b). The number of TUNEL+ apoptotic
β-cells, which was increased in HFD-fed hIAPP+ mice, was
significantly reduced by MSL-7 treatment for 8 weeks as well
(Fig. 6c). Accordingly, β-cell mass determined after insulin
immunohistochemistry which was reduced in hIAPP+ mice on
HFD was significantly recovered by MSL-7 treatment for 8 weeks
(Fig. 6d). Insulin content of the pancreas which was reduced in
hIAPP+ mice on HFD was also restored by MSL-7 treatment for
8 weeks (Fig. 6e). When we studied whether MSL-7 administra-
tion could change the distribution of MiTF/TFE family members
in pancreatic islets in vivo, nuclear translocation of TFEB and
TFE3 in islet cells was clearly observed after 8 weeks of MSL-7
administration as evidenced by cyan nuclei due to colocalization
of TFEB and TFE3 fluorescence with nuclear DAPI (Fig. 6f),
suggesting that increased activity of MiTF/TFE family members
leading to increased autophagic activity is responsible for the
increased clearance of islet hIAPP oligomer in vivo and improved
β-cell function.
We also studied whether MSL-7 could enhance in vivo
clearance of hIAPP oligomer that accumulates through mechan-
isms other than HFD feeding of hIAPP+ mice. When we
administered MSL-7 to hIAPP+ mice treated with a low dose of
streptozotocin (STZ) that has been reported to induce accumula-
tion of hIAPP amyloid without causing extensive β-cell destruc-
tion5, contents of hIAPP oligomer and islet amyloid in pancreatic
islets of STZ-treated hIAPP+ mice were significantly reduced
(Supplementary Fig. 8a, b), suggesting that MSL-7 is able to
expedite clearance of hIAPP oligomer and amyloid accumulating
through diverse pathways. Consistently, elevated nonfasting
blood glucose and glucose intolerance after STZ administration
to hIAPP+ mice were significantly reduced by MSL-7 treatment
in vivo (Supplementary Fig. 8c, d).
To finally confirm that effect of MSL-7 improving metabolic
profile of hIAPP+ mice on HFD is due to enhanced autophagy or
TFEB activation in pancreatic β-cells, we generated hIAPP+ mice
with β-cell-specific Tfeb-KO (hIAPP+TfebΔβ-cell) by breeding
hIAPP+ mice with RIP-Cre × TfebF/F mice. Nonfasting or fasting
blood glucose level after HFD feeding was further increased in
hIAPP+TfebΔβ-cell mice compared to HFD-fed control hIAPP+
TfebF/F mice probably due to reduced autophagy or lysosomal
function in β-cells, while body weighs were not different between
groups (Supplementary Fig. 9a–c). HFD-induced impairment of
glucose tolerance measured by AUC of GTT curves and HFD-
induced decrease of insulinogenic index in control hIAPP+TfebF/F
mice were also aggravated in hIAPP+TfebΔβ-cell mice (Supple-
mentary Fig. 9d, e), again probably due to reduced constitutive
autophagy or lysosomal function by β-cell-specific Tfeb-KO.
In these mice, we studied whether in vivo effects of MSL-7 is
affected by Tfeb of β-cells. We started MSL-7 treatment
of hIAPP+TfebΔβ-cell mice at the age of 8 weeks (Fig. 7a)
because nonfasting blood glucose began to rise in 8-week-old
hIAPP+TfebΔβ-cell mice on NCD (see Supplementary Fig. 9a),
and it might be difficult to compare MSL-7 effect between
hIAPP+TfebΔβ-cell and hIAPP+TfebF/F mice on HFD if basal
nonfasting glucose levels before MSL-7 treatment were signifi-
cantly different between these mice. In hIAPP+TfebΔβ-cell mice on
HFD, reduction of nonfasting or fasting blood glucose by MSL-7
treatment (differences between orange and violet lines or bars in
Fig. 7b, c) was statistically insignificant and less compared to
that in hIAPP+TfebF/F mice on HFD (differences between blue
and red lines or bars in Fig. 7b, c) without differences of body
weight between groups (Fig. 7d), supporting that enhanced
TFEB activation or autophagy contributes to the improved
glucose profile of MSL-7-treated hIAPP+ mice on HFD.
Improvement of glucose tolerance measured by AUC of GTT
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20454-z ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:183 | https://doi.org/10.1038/s41467-020-20454-z | www.nature.com/naturecommunications 9
curves or that of insulinogenic index after MSL-7 administration
to hIAPP+TfebΔβ-cell mice on HFD (differences between orange
and violet lines or bars in Fig. 7e, f) was also statistically
insignificant and less compared to that in hIAPP+TfebF/F mice on
HFD (differences between blue and red lines or bars in Fig. 7e, f),
suggesting the role of enhanced TFEB activation or autophagy in
the improvement of glucose tolerance and β-cell function by
MSL-7 administration to hIAPP+ mice on HFD. Consistently,
reduction of hIAPP oligomer or FSB-stained islet amyloid
accumulation after MSL-7 administration to hIAPP+TfebΔβ-cell
mice on HFD (differences between orange and violet bars in
Fig. 7g, h) was statistically insignificant and less compared to that
in hIAPP+TfebF/F mice on HFD (differences between blue and
red bars in Fig. 7g, h).
Discussion
We here have demonstrated that the autophagy enhancer small
molecule, MSL-7 that could improve metabolic profile of obese
mice by activating TFEB and enhancing lysosomal biogenesis or
autophagy gene expression, can also improve glucose profile and
pancreatic β-cell function of transgenic mice expressing amyloi-
dogenic hIAPP fed HFD. Improvement of pancreatic β-cell
function in vivo can be explained by expedited clearance of
hIAPP oligomer and amelioration of pancreatic β-cell death
caused by hIAPP oligomer accumulation. MSL-7-induced
reduction of amyloidogenic IAPP oligomer accumulation and
resultant cell death in the presence of 3-MA was observed not
only when hIAPP was overexpressed by genetic methods but also
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Fig. 6 Pancreatic islets of hIAPP+ mice treated with MSL-7. a Percentage of A11 puncta+ cells among total DAPI+ islet cells in pancreatic sections from
HFD-fed hIAPP+ mice treated with MSL-7 for 8 weeks was determined by confocal microscopy (F= 498.6, df treatment= 3, df residual= 20) (right).
Representative pictures are shown (left). Inset images were magnified. Arrow heads indicate islet cells with pyknotic nuclei (n= 6 each, 132–148 islets per
group). b Mean fluorescence intensity of FSB staining per islet area was determined using ImageJ (F= 178.3, df treatment= 3, df residual= 20) (right).
Representative pictures are shown (left). (n= 6 each, 151–156 islets per group). c Percentage of TUNEL+ β-cells among total β-cells in sections of HFD-fed
hIAPP+ mice treated with MSL-7 was calculated (F= 31.5, df treatment= 3, df residual= 20) (right). Representative TUNEL staining is shown (left). Insets
(TUNEL+ β-cells) were magnified. (n= 6 each, 180–182 islets per group). d Relative β-cell mass in HFD-fed hIAPP+ mice treated with MSL-7 was
determined by insulin immunohistochemistry and point counting (F= 22.2, df treatment= 3, df residual= 20) (right). Representative insulin
immunochemistry is shown (left). (n= 6 each, 180–182 islets per group). e Insulin content of pancreatic islets from HFD-fed hIAPP+ and hIAPP− mice
treated with MSL-7 was measured by ELISA, which was normalized to the total pancreas weight (F= 9.5, df treatment= 3, df residual= 18). (n= 5
for Veh-treated hIAPP− mice, n= 5 for MSL-7-treated hIAPP− mice, n= 6 for Veh-treated hIAPP+ mice and n= 6 for MSL-7-treated hIAPP+ mice).
f Immunfluorescence of pancreatic sections from HFD-fed hIAPP+ and hIAPP− mice treated with MSL-7 using anti-TFEB (left) and anti-TFE3 antibodies
(right). Insets were magnified to show colocalization of TFEB/TFE3 with nuclear DAPI. (n= 6 each) All data in this figure are the means ± SEM from more
than 3 independent experiments. (scale bar, 100 μm) **P < 0.01; ***P < 0.001 by one-way ANOVA with Tukey’s test.
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amyloidogenic sIAPP or hiPSC-derived β-cells expressing hIAPP
were employed, suggesting physiological relevance of MSL-7
effect improving pancreatic β-cell viability. In addition to the
reduction of hIAPP oligomer-mediated β-cell death, ameliorated
mitochondrial dysfunction by MSL-7 may also contribute to the
improved β-cell function of HFD-fed hIAPP+ mice because
hIAPP oligomer can cause mitochondrial damage and mito-
chondrial function is crucial in the insulin release in response to
glucose27,28. While we observed similar cell death following
inhibition of autophagy in both genetic overexpression of hIAPP
and endogenous amyloidogenic hIAPP models, accumulated
hIAPP species were different between them because pro-hIAPP
dimer or trimer was observed in INS-1 cells transfected with
prepro-hIAPP-HA, while hIAPP oligomer stained with A11
antibody was observed in hiPSC-derived β-cells expressing
endogenous amyloidogenic hIAPP. We have no direct biochem-
ical evidence showing the progression from pro-hIAPP dimer to
high-n hIAPP oligomer or amyloid. However, we have observed
the proportional relationship between pro-hIAPP dimer and
hIAPP oligomer in the same cells – monkey islet cells transfected
with prepro-hIAPP-HA3, and it is likely that (pro-)hIAPP dimer
or trimer acts as a seed for high-n hIAPP oligomer16. Our study
also suggests the possibility that while pro-hIAPP dimer may exist
in unstressed β-cells and is not cytotoxic, further progression into
high-n oligomer occurs in the presence of autophagy impairment
or metabolic stress3. It should also be noted that A11 antibody
that was raised against human Aβ oligomer and has been used to
detect hIAPP oligomer, can recognize other proteins such as heat-
shock proteins31.
Metabolic effect of MSL-7 appears to be due to the activation of
the MiTF/TFE family members enhancing autophagic activity
and lysosomal function. In our CRISPR/Cas9 KO experiments,
both Tfeb and Tfe3 appear to contribute to the expedited clear-
ance of hIAPP oligomer and reduced cell death by MSL-7 because
the reduction of hIAPP dimer accumulation and hIAPP-
associated cell death by MSL-7 became statistically insignificant
by KO of either Tfeb or Tfe3, suggesting additive effects of Tfeb
and Tfe3 in the protection of insulinoma cell death by MSL-7.
Consistently, dephosphorylation and nuclear translocation by
MSL-7 occurred in both TFEB and TFE3 proteins, which could be
dependent on calcineurin9. Nuclear translocation of both TFEB
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Fig. 7 Role of pancreatic β-cell Tfeb in MSL-7-induced metabolic improvement. a Scheme of MSL-7 administration to hIAPP+TfebΔβ-cell mice. b Nonfasting
blood glucose was monitored weekly during MSL-7 treatment (F= 28.0, df= 3). (n= 5 each). c Fasting blood glucose in HFD-fed hIAPP+TfebΔβ-cell and
hIAPP+TfebF/F mice treated with MSL-7 (F= 23.2, df treatment= 3, df residual= 16). (n= 5 each). d Body weight before and during MSL-7 treatment of
HFD-fed hIAPP+TfebΔβ-cell and hIAPP+TfebF/F mice. (n= 5 each). e GTT in HFD-fed hIAPP+TfebΔβ-cell or hIAPP+TfebF/F mice treated with MSL-7 (F= 26.9,
df= 3) (left). AUC was calculated (F= 23.4, df treatment= 3, df residual= 16) (right). (n= 5 each). f Insulinogenic index in HFD-fed hIAPP+TfebΔβ-cell or
hIAPP+TfebF/F mice treated with MSL-7 (F= 21.0, df treatment= 3, df residual= 16) (left). Serum insulin before and 15min after glucose injection (right).
(n= 5 each). g Percentage of A11+ cells among total islet cells in sections of HFD-fed hIAPP+TfebΔβ-cell or hIAPP+TfebF/F mice treated with MSL-7 (F= 40.9,
df treatment= 3, df residual= 16) (right). Representative pictures were presented (left). Inset images were magnified. (n= 5 each, 36–45 islets). h Mean
pixel intensity of FSB per islet area in sections from HFD-fed hIAPP+TfebΔβ-cell or hIAPP+TfebF/F mice treated with MSL-7 (F= 32.0, df treatment= 3, df
residual= 16) (right). Representative pictures were presented (left). (n= 5 each, 40–51 islets). All data in this figure are the means ± SEM from more than 3
independent experiments. (scale bar, 100 μm) #P or *P < 0.05; ##P or **P < 0.01; ###P or ***P < 0.001 by two-way ANOVA with Bonferroni’s test (b, e) and
one-way ANOVA with Tukey’s test (c, e, f, g, h). (#, comparison between MSL-7-treated hIAPP+TfebF/F and Veh-treated hIAPP+TfebF/F mice; *, comparison
between Veh-treated hIAPP+TfebΔβ-cell and Veh-treated hIAPP+TfebF/F mice in b, e). (n.s. not significant).
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in vivo, which appears to be responsible for reduced hIAPP oli-
gomer/amyloid accumulation in pancreatic islets, ameliorated
pancreatic β-cell death, enhanced the pancreatic β-cell function
and improved the glucose tolerance of HFD-fed hIAPP+ mice.
Direct evidence supporting the role of pancreatic β-cell TFEB
in the clearance of hIAPP oligomer was obtained using β-cell-
specific Tfeb-KO mice crossed to hIAPP+ mice. In those hIAPP+
TfebΔβ-cell mice on HFD, blood glucose profile, glucose tolerance
and insulinogenic index were further deteriorated compared to
control hIAPP+TfebF/F mice on HFD. Moreover, improvement of
these metabolic parameters by MSL-7 administration was also
diminished in hIAPP+TfebΔβ-cell mice on HFD, indicating in vivo
role of β-cell TFEB in MSL-7-mediated clearance of hIAPP
oligomer.
We have previously reported that autophagy enhancers such as
MSL-7 could be a therapeutic agent against diabetes or metabolic
syndrome associated with obesity based on our data using mouse
models. However, human diabetes is different from murine dia-
betes in that islet amyloid is found in most patients with type 2
diabetes due to the amyloidogenic propensity of hIAPP2,32. Since
the aggregate-prone or amyloid proteins are cleared preferentially
by autophagy rather than by the proteasomal degradation path-
way6, the role of autophagy or the effect of autophagy modulators
may be more important in human type 2 diabetes than in murine
type 2 diabetes, which was strengthened by our observation that
MSL-7 can expedite clearance of hIAPP oligomer accumulation
in hiPSC-β-cells and protect those cells from hIAPP oligomer-
induced cell death. MSL-7 or other autophagy enhancers could be
therapeutic agents against human diabetes associated with islet
amyloid accumulation.
Methods
Animals. hIAPP+ mice expressing hIAPP under the control of the rat insulin II
promoter (FVB/N-Tg (Ins2-IAPP) RHFSoel/J mice, Stock No. 008232, Jackson
Laboratory) were maintained on an FVB/N background, and genotyping was
conducted by PCR analysis of tail DNA using specific primers (forward, 5’-GTC
ATGTGCACCTAAAGGGGCAAGTAATTCA-3’; reverse, 5’-CGAGTGGGCTAT
GGGTTTGT-3’)3. TfebF/F mice were generated by breeding Tfebtm1a(EUCOMM)Wtsi
mice (Mutant Mouse Resource and Research Center, MMRRC) with FLPeR mice
(Wellcome Trust Sanger Institute). hIAPP+ mice with targeted disruption of Tfeb
in pancreatic β-cells were generated by crossing RIP-Cremice (Jackson Laboratory)
with TfebF/F mice and then with hIAPP+ mice (hIAPP+TfebΔβ-cell mice). GTT was
conducted by the intraperitoneal injection of 1 g/kg glucose to overnight fasted
mice. Blood glucose concentration was measured using a One Touch glucometer
(Lifescan) at 0, 15, 30, 60, 120, and 180 min after glucose injection3. ITT was
performed by intraperitoneal injection of 1 U/kg regular insulin to fasted mice and
measuring blood glucose levels at 0, 15, 30, 60, 120, and 180 min after insulin
injection33. Serum insulin levels before and 15 min after the glucose challenge were
measured using an ELISA kit (Shibayagi Co.) to calculate insulinogenic index
(Δinsulin15min/Δglucose15min)3.
Cynomolgus monkeys purchased from Guangxi Grandforest Scientific Primate
Company Ltd. were maintained in the Orientbio Animal Facility3.
All animals were maintained in a specific pathogen free (SPF) facility accredited
by the Association for the Assessment and Accreditation of Laboratory Animal
Care International (AAALAC). All animal experiments were approved by the
Institutional Animal Care and Use Committee of Yonsei University Health System
(IACUC of YUHS) and were conducted in accordance with the Public Health
Service Policy on Humane Care and Use of Laboratory Animals. Monkey
experiments were approved by the IACUC of Orientbio, another AAALAC-
accredited unit.
MSL-7 was dissolved in DMSO to make 125 mg/ml stock solution, and diluted
with PBS to 5 mg/ml for injection (50 mg/kg, intraperitoneally 3 times a week for
8 weeks). To study MSL-7 effect on STZ-induced hIAPP oligomer accumulation,
STZ (Sigma) dissolved in 0.1 M citrate buffer, pH 4.5, was injected into mice
intraperitoneally to 2-month-old male hIAPP+ mice at a dose of 80 mg/kg.
Twenty-four h later, MSL-7 administration was started and continued every other
day for a total of 3 times.
Isolation of pancreatic islets. Primary monkey islet cells were isolated using the
modified Ricordi’s method34 as previously described3. In brief, the pancreas dis-
sected from a 60-month-old male monkey was placed in 4 °C HTK solution for
distention with 3–4 ml/g pancreas cold Liberase MTF C/T solution (Roche Custom
Biotech). The distended pancreas was placed in an isolation chamber equipped
with a peristaltic pump, and the temperature was raised to 37 °C. The isolation
chamber was gently shaken during digestion, and serial samples were examined
under a light microscope after dithizone (Sigma Aldrich) staining. When liberated
pancreatic islets were observed, Dilution Solution (Corning) was added to inacti-
vate Liberase MTF C/T. Digested cells collected into 200 ml conical tubes were
washed with Washing Solution (Corning). Islets were then isolated by continuous
density gradient centrifugation using a COBE 2991 Cell Processor (Terumo BCT
Inc.) in iodixanol density gradient media (OptiprepTM Axis-Shield, Alere Tech-
nologies AS) for culture in CMRL1066-10% FCS at 37 °C.
Primary murine islets were isolated from fasted mice using the collagenase
digestion technique as previously described35. In brief, after injection of 2.5 ml of
collagenase P (0.8 mg/ml) into the common bile duct, the pancreas was procured
and incubated in a collagenase solution at 37 °C for 13 min 20 s. After cessation of
enzymatic digestion with cold HBSS-5% FCS, tissue was passed through a 400 μm
sieve and then centrifuged on 1.10, 1.085, 1.069 and 1.037 g/ml Biocoll gradients
(Biochrom). Islets were collected from the interface using micropipettes.
Cells. INS-1 cells (kindly provided by Dr. C. Wollheim, University of Geneva) were
cultured in RPMI-1640 supplemented with 10% FCS, 1 mM sodium pyruvate
(Sigma-Aldrich), 10 mM HEPES (Corning), 50 μM 2-mercaptoethanol (Sigma-
Aldrich) and 100 U/ml penicillin-100 μg/ml streptomycin (Lonza) (passage num-
ber, 89). 1.1B4 cells were obtained from ECACC (Salisbury) through Fadzilah
Adibah Abdul Majid (Universiti MalaysiaTerengganu), and cultured in RPMI
1640-10%FCS-100 U/ml penicillin-100 μg/ml streptomycin (passage number, 35).
MSL-7 was dissolved in DMSO to obtain 20 mM stock solution and directly diluted
to the final concentrations in culture medium for in vitro experiments. All cells
were free of mycoplasma contamination. All in vitro experiments were repeated at
least three times to confirm reproducibility.
hiPSC generation and differentiation into insulin-producing cells. hiPSCs were
derived by umbilical cord blood mononuclear cells, and reprogramming was
conducted using CytoTune-iPS Sendai Reprogramming Kit (Life Technologies).
Healthy human cord blood had been obtained from newborn after obtaining
informed parental consent at Catholic Hematopoietic Stem Cell Bank of Korea.
hiPSCs were adapted to feeder-free conditions on vitronectin (VTN-N) (Gibco)-
coated plates in TeSRTM-E8TM medium (STEMCELL Technologies). These cells
were incubated at 37 °C in a 5% CO2 atmosphere, and the medium was changed
daily. To initiate differentiation, confluent hiPSCs were dissociated into single cell
suspension using TrypLE and seeded at 1.0 × 106 cells per well in AggrewellTM 400
plates (STEMCELL Technologies) for incubation in AggreWellTM medium with
10 μM Rho kinase inhibitor (Y-27632). After 24 h of incubation, aggregated cells
were differentiated into insulin-producing cells using STEMdiffTM Pancreatic
Progenitor Kit (STEMCELL Technologies). At the stage for pancreatic progenitor
generation, 0.25 μM SANT1 (Sigma-Aldrich) was added for the last 2 days. Cells
were then cultured in CMRL medium (Welgene) containing 25 ng/ml human HGF
(PeproTech), 10 mM nicotinamide (Sigma-Aldrich), 20 ng/ml Exendin-4 (Pro-
Spec), 1 μM T3 (Sigma-Aldrich) and 10 μM Alk5 inhibitor (Biogems) for 6 days to
produce insulin-producing cells. For immunofluorescence or TUNEL staining of
iPSC-β-cells, islet-like clusters were pre-embedded in agar before paraffin
embedding. All experiments using hiPSC were conducted in accordance with the
protocol approved by the IRB of the Catholic University of Korea.
TUNEL staining and β-cell mass. Deparaffinized pancreatic sections were incu-
bated with TUNEL reagent (Roche Applied Science) and DAB (Life Technologies)
as the color substrate. Insulin immunochemistry was then conducted by serial
incubation with anti-insulin antibody (Cell Signaling Technology, 1:150), bioti-
nylated anti-rabbit antibody (Vector Laboratories, 1:100), streptavidin-alkaline
phosphatase, and then with Vector® Blue alkaline phosphatase substrate3 (Vector
Laboratories). The percentage of TUNEL+ cells among total β-cells was determined
in more than 30 islets per mouse (more than 180 islets per group) by manual
counting under BX43 microscope (Olympus). To detect TUNEL+ cells among
hiPSC-β-cells, TUNEL staining was followed by incubation with anti-insulin
antibody and then with Alexa 594-anti-mouse IgG (Life Technologies, 1:200)
which was subjected to fluorescent confocal microscopy using LSM700 microscope
(Carl Zeiss). The percentage of TUNEL+ cells among insulin+ cells was deter-
mined in more than 20 islet-like clusters by manual counting. Relative β-cell mass
was determined by analyzing more than 30 islets per mouse (more than 180 islets
per group). After insulin immunohistochemistry using anti-insulin antibody and
DAB, point counting morphometry was conducted as previously described3.
IAPP expression in vitro. The transient transfection of prepro-hIAPP-HA and
prepro-mIAPP-HA3 was conducted using jetPEI® DNA transfection reagent
(Polyplus Transfection)3. To block autophagy of transfected cells, after 24 h of
transfection, the culture medium was changed to a new medium containing 5 mM
3-MA (Sigma Aldrich) or 10 nM bafilomycin A1 (Sigma Aldrich). After another
16 h of incubation with or without MSL-7, cells were subjected to electrophoretic
separation after lysis, immunofluorescence or oligonucleosome detection by
ELISA3.
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Generation of CRISPR/Cas9 KO cells. To make Tfeb-KO or Tfe3-KO INS-1 cells,
cells were transfected with 2 μg each of sgRNA plasmid (Tfeb sgRNA1, CATGC
AGCTCATGCGGGAGCAGG; Tfeb sgRNA2, TGAACTGGGGTGTTGATG
GCTGG; Tfe3 sgRNA1, TGCTGCGGCAGCAGCTTATGAGG; Tfe3 sgRNA2,
GGGGTGGACGACTCAATGTGTGG), and Cas9-Puro2A-RFP using jetPEI®
DNA transfection reagent (Polyplus Transfection). After puromycin selection,
genomic DNA was isolated, followed by two rounds of PCR using specific primers
(Tfeb 1st-F, AGGGCAGGAACAGGATGATG; Tfeb 1st-R, CCAGCAGAGTTGC
AAGACGA; Tfeb 2nd-F, GATGTGGATGTGACAGCGAG; Tfeb 2nd-R, GACTG
TTGGGGGCACTGTTG; Tfe3 1st-F, GCTCCAGCGTAGGTTTAGCA; Tfe3 1st-R,
CACGAGGACCCTGAGTGATG; Tfe3 2nd-F, TAGCTTACCTGTGGCCCTGT;
Tfe3 2nd-R, GGACCCTGAGTGATGATTCCT) and a T7E1 cleavage assay using a
kit (New England Biolabs). Cells with mismatched mutations were isolated by the
low-density seeding method. Gene KO was confirmed by nucleotide sequencing
using an automatic DNA analyzer (Bioneer).
Confocal microscopy. Immunofluorescence of MiTF/TFE family members in INS-
1 cells, 1.1B4 cells or primary pancreatic islet cells was conducted using anti-TFEB
(Bethyl Laboratories, 1:150), anti-TFE3 (Sigma Aldrich, 1:150), or anti-MiTF
(Thermo Fisher Scientific, 1:150) as the primary antibodies. For TFEB immunos-
taining of INS-1, 1.1B4 or primary islet cells, cells with nuclear TFEB were con-
sidered to be activated even though residual cytosolic TFEB is detected because
TFEB staining was observed only in the cytoplasm and nuclear TFEB was almost
completely absent in most of untreated cells, while nuclear TFEB staining with
residual cytosolic TFEB staining was seen after treatment with MSL-7. For TFE3
immunostaining, cells with bright nuclear TFE3 without cytosolic TFE3 were
considered to be activated because faint nuclear TFE3 was observed in untreated
cells, while bright nuclear TFE3 staining without cytosolic TFE3 staining was
observed in most cells after MSL-7 treatment. The percentage of cells with nuclear
TFEB or TFE3 among total DAPI+ cells was determined by counting more than
100 cells from more than 5 fields manually.
hIAPP oligomer in frozen tissue sections or in cells cultured in a Lab-Tak® II
Chamber Slide (Thermo Fisher Scientific) was identified by immunostaining using
A11 antibody (Merck Millipore, 1:150) and Alexa 488-anti-rabbit IgG (Life
Technologies, 1:200). To analyze IAPP oligomer accumulation in cultured cells,
confocal microscopy was conducted using LSM700 microscope, and the numbers
of A11+ puncta in more than 20 cells were counted manually. To study hIAPP
oligomer accumulation in the pancreas, the percentage of A11+ cells among total
DAPI+ islet cells in pancreatic sections was determined by manually counting
more than 20 islets per mouse (more than 132 islets per group). To investigate
colocalization of A11 puncta with autophagosome, immunostaining using A11
antibody was followed by immunostaining using anti-LC3 antibody (MBL, 1:150)
and then with Alexa 594-anti-mouse IgG (Life Technologies, 1:200). Confocal
microscopy was conducted using LSM700 microscope, and the number of yellow
puncta (autophagosome colocalized with A11) was counted manually in more than
20 cells.
Amyloid staining. FSB staining for tissue amyloid was conducted using a mod-
ification of previously reported methods36,37. Briefly, pancreatic sections were
deparaffinized in xylene and hydrated down to 30% ethanol. Deparaffinized sec-
tions were incubated in 70% formic acid for 20 min. After incubation with 10 μM
FSB (Merck Millipore) for 1 h at room temperature with light protection, sections
were subjected to fluorescent microscopy using BX53F fluorescent microscope
(Olympus). Mean pixel intensity per islet area was determined in more than 25
islets per mouse (more than 151 islets per group) using ImageJ software (NIH).
Transfection and plasmids. Cells were transiently transfected with plasmids such
as Tfeb-GFP or Tfe3-GFP using jetPEI® DNA transfection reagent. Nuclear
translocation of Tfeb-GFP or Tfe3-GFP was determined after treatment of trans-
fected INS-1, 1.1B4 or primary monkey islet cells with MSL-7 for 4 h by confocal
microscopy. To examine autophagosomes and autophagolysosomes, tandem
mRFP-GFP-LC3 was transfected using lipofectamine 2000 (Life Technologies).
Confocal microscopy was conducted after treatment of transfected cells with MSL-
7 for 4 h using LSM700 microscope. GFP or RFP puncta were defined as non-
nuclear punctate structures with discrete fluorescent signal on a dark background
which was clearly visible with fluorescent confocal microscopy. The numbers of
yellow puncta (autophagosomes) and red puncta (autophagolysosomes) in more
than 20 cells were counted manually.
Immunoblot analysis and antibodies. Cells were lysed with a buffer (1% SDS,
100 mM Tris, pH 7.5, 0.5% Triton X-100) containing protease and phosphatase
inhibitors. Protein concentration was determined using the Bradford method.
Samples (5–10 μg) were separated on 4–12% Bis-Tris gel (NuPAGE®, Life Tech-
nologies), and transferred to nitrocellulose membranes (Merk Millipore) for
immunoblot analysis using the enhanced chemiluminescence (ECL) method
(Dongin LS). Antibodies against the following proteins were used: SQSTM1
(Progen Biotechnik, 1:5000), LC3 (Novus Biologicals, 1:1000), TFEB (Bethyl
Laboratories, 1:1000), TFE3 (Sigma Aldrich, 1:1000), phospho-S142-TFEB (Merk
Millipore, 1:1000), phospho-(Ser) 14-3-3 binding motif (Cell Signaling Technology,
1:1000), 14-3-3 protein (Cell Signaling Technology, 1:1000), β-actin (ACTB) (Santa
Cruz Biotechnology, 1:4000), HA (Cell Signaling Technology, 1:1000) or Lamin A
(Santa Cruz Biotechnology, 1:1000). Densitometry of the protein bands was per-
formed using ImageJ.
Immunoprecipitation. After lysis of Tfeb-GFP or Tfe3-GFP transfectant or non-
transfectant INS-1 cells treated with MSL-7 for 4 h in ice-cold lysis buffer (400 mM
NaCl, 25 mM Tris–HCl, pH 7.4, 1 mM EDTA, and 1% Triton X-100) containing
protease and phosphatase inhibitors, lysates were centrifuged at 13,000 × g for 10
min in a microfuge tube and incubated with anti-GFP (1:1000, AbFrontier), anti-
TFEB (Bethyl Laboratories, 1:1000) or anti-TFE3 antibody (Sigma Aldrich, 1:1000)
in binding buffer (200 mM NaCl, 25 mM Tris–HCl, pH 7.4, 1 mM EDTA) with
constant rotation at 4 °C for 1 h. After adding 50 μl of 50% of Protein-G beads
(Roche Applied Science) slurry to the lysates and incubation with rotation at 4 °C
overnight, resins were washed with binding buffer. After resuspension of the pellet
in a Sample buffer (Life Technologies) and heating at 100 °C for 3 min, the
supernatant was collected by centrifugation at 13,000 × g for 20 s for electro-
phoretic separation in a NuPAGE® gradient gel (Life Technologies). Immuno-
blotting was conducted using primary antibody (anti-phospho-(Ser) 14-3-3
binding motif antibody (1:1000) or anti-pan 14-3-3 antibody (1:1000) from Cell
Signaling Technology), horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(Cell Signaling Technology), and then, an ECL kit for detection of
chemiluminescence.
Cell fractionation. After washing cells with chilled PBS (all subsequent steps, on
ice), 200 μl of a lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, 0.05% Igepal containing protease and phosphatase inhibitors) was
added to each well of a 6-well plate. After scraping cells and douncing, the extract
was centrifuged at 845 × g for 10 min. Nuclear fraction was resuspended in a buffer
containing 5 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
26% glycerol (v/v) and 300 mM NaCl. Both nuclear and cytoplasmic fractions were
resuspended in a sample buffer (Life Technologies) for immunoblot analysis.
RNA extraction and real-time RT-PCR. cDNA was synthesized using total RNA
extracted from cells with TRIzol (Life Technologies) and M-MLV Reverse Transcriptase
(Promega) according to the manufacturer’s protocol. Real-time RT-PCR was performed
using AccuPower® GreenStarTM qPCR master mix (Bioneer) in a QuantStudio3 Real-
Time PCR System (Applied Biosystems). All expression values were normalized to
Rpl32 mRNA level. The sequences of primers used for real-time RT-PCR are listed in
the Supplementary Tables 1 and 2. Expression of MiTF/TFE family genes in primary
mouse islets was studied by RT-PCR using specific primers (Tfeb F, GGTCTTGGGC
AAATCCCTTC; Tfeb R, CATGGCAGCTGTTGGTTCG; Tfe3 F, CCGTGTTCCTGC
TATTGGAA; Tfe3 R, CGTAGAAGCTGTCAGGATCG; Mitf F, GAAGTCGGGGA
GGAGTTTCA; Mitf R, GCCACTCTCTGTTGCATGA).
Islet cell death. Primary monkey islets or 1.1B4 cells were placed on a Cell Culture
Plate (SPL Life Sciences), and incubated with MSL-7 in the presence or absence of
5 mM 3-MA for 16 h. Apoptosis was quantified by measuring the amount of
oligonucleosomes in cell lysate by ELISA employing a kit (Roche Applied Science),
according to the manufacturer’s instruction. Apoptosis of wild-type INS-1 cells,
Tfeb-KO or Tfe3-KO INS-1 cells after transfection of prepro-IAPP-HA was deter-
mined using the same method of oligonucleosome detection.
Pancreatic insulin content. Pancreatic insulin was extracted and insulin content
was measured by ELISA according to the protocol recommended by the manu-
facturer, and normalized to the total pancreas38.
O2 consumption of islets. O2 consumption of isolated mouse islets was measured
using Seahorse Extracellular Flux (XFe96) Analyzer (Agilent Technologies)
according to a modification of the manufacturer’s protocol. In brief, islets were
seeded into wells of a poly-L-lysine-coated XF96 spheroid microplate (25 islets/
well). Islet seeding was done by inserting pipette tip directly over the central
depressed chamber into the wells of the spheroid microplate. Islets then were
incubated with pre-warmed XF assay medium (Seahorse XF base DMEM medium
supplemented with 3 mM glucose, 1% fetal bovine serum, 1 mM sodium pyruvate
and 2 mM glutamine) for 1–2 h at 37 °C in a non-CO2 incubator. Mitochondrial
respiration was measured using the Seahorse extracellular flux analyzer equipped
with a spheroid microplate-compatible thermal tray. Basal respiration was first
measured in XF assay medium containing 3 mM glucose. Islets were then
sequentially exposed to 20 mM glucose, 5 μM oligomycin, 1 μM carbonyl cyanide-
4-(trifluoromethoxy)phenylhydrazone (FCCP) and 5 μM rotenone in combination
with 5 μM antimycin A (Rot/AA) at the indicated time points to measure glucose-
stimulated, ATP-coupled, maximal and non-mitochondrial O2 consumption,
respectively. O2 consumption was analyzed using a software (WaveTM, Agilent
Technologies).
Statistical analysis. All values are expressed as the means ± SEM of more than 2
independent experiments. Two-tailed Student’s t-test was used to compare values
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between two groups. One-way ANOVA with Tukey’s test or two-way ANOVA
with Bonferroni’s test was employed to compare values between multiple groups.
P values < 0.05 were considered significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data generated or analyzed during this study are available from the corresponding
author on reasonable request. Source data are provided with this paper.
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